Načítá se...
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
The current standard treatment option for advanced hepatocellular carcinoma (HCC) is sorafenib, but its clinical benefit is modest. In spite of many attempts, few drugs can provide any significant improvement of survival as the first- or second-line therapy of choice in phase III randomized controll...
Uloženo v:
| Vydáno v: | World J Gastroenterol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4427665/ https://ncbi.nlm.nih.gov/pubmed/25987766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i18.5445 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|